Note 6 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Nov. 26, 2019	Mar. 31, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (11,880,000)	$ (16,811,000)
Assets, Current, Total		14,964,000	15,298,000
Liabilities, Current, Total		6,348,000	6,143,000
Amortization of Debt Discount (Premium)		$ 3,631,000	$ 5,558,000
Boyalife Asset Holding II [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage		22.00%	22.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80	$ 1.80
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 10,000,000
Long-term Line of Credit, Total			$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage		22.00%
Amortization of Debt Discount (Premium)		$ 3,310,000	2,931,000
Interest Payable		$ 2,231,000	$ 2,082,000
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	12,000,000
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	500,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage		8.64%		18.79%	20.00%
Dilution Gain from Equity Method Investments		$ 262,000
Equity Method Investment Accumulated Gain Loss		(428,000)
Equity Method Investment, Aggregate Cost		0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		(666,000)
Assets, Current, Total		3,177,000
Liabilities, Current, Total		$ 1,946,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.16%	80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage				6.05%